Advanced Search

ETF Components for CHNA - Loncar China BioPharma ETF


Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

Holdings

Symbol Grade Price % Change Allocation
GTH D 0.00 1.43
CASI F 0.00 0.90

Represented by ETF Holdings

Keywords: Cancer Cancer Treatment Advanced Solid Tumors Autoimmune Disease Autoimmune Diseases Biology Biotechnology Cancer Care Cell Cycle Cyclacel Diseases Leukemia Life Sciences Molecular Biology Multiple Myeloma Oncology Ovarian Cancer Pacritinib Pharmaceutical Platinum
Industries: Diagnostics & Research

Recent News for Loncar China BioPharma ETF & its Holdings

Date Stock Title
Apr 13 GTH Genetron Health Releases 22 New Research Results at American Association for Cancer Research Annual Meeting (AACR) 2021
The investment seeks to track the performance, before fees and expenses, of the Loncar China BioPharma Index (the index). Under normal circumstances, at least 80% of the fund's total assets (exclusive of any collateral held from securities lending) will be invested in the component securities of the index or in depositary receipts representing such component securities. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries. The fund is non-diversified.
Exchange Traded Fund ETF Institutional Investors Short Selling Lonca Loncar Cancer Immunotherapy Index
Back to the Main CHNA Page...